{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:18:25Z","timestamp":1790806705947,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"3pt2","license":[{"start":{"date-parts":[[2017,2,5]],"date-time":"2017-02-05T00:00:00Z","timestamp":1486252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Roche Molecular Systems, Inc.,"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Zika virus (ZIKV) has spread in the Americas, including parts of the southern United States, and infection can be associated with serious complications, including congenital brain abnormalities. Probable transfusion transmission of ZIKV has been documented in Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Preemptive testing of blood donations for ZIKV RNA was implemented in southern US states at risk of local transmission using a test approved under a Food and Drug Administration (FDA) investigational new drug application, cobas Zika. Screening was expanded after issuance of an updated FDA guidance. Donations reactive on initial screening were further tested by nucleic acid and antibody tests to determine the donor status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 358,786 donations from US states screened by individual donation testing, 23 were initially reactive on cobas Zika. Fourteen of these represented probable ZIKV infection based on reactivity on additional nucleic acid testing or anti\u2010Zika immunoglobulin M. Ten of the 14 donors reported travel to an identified ZIKV\u2010active area within 90 days before donation (median time from end of travel to donation, 25 days; range, 6\u201071 days). Three donors with travel history also had a potential sexual exposure. Only seven of the 14 donations with probable ZIKV infection were detectable upon 1:6 dilution to simulate minipool testing. The estimated specificity of the cobas Zika test was 99.997%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Screening of donations for ZIKV RNA can interdict ZIKV\u2010infected donors. Donor risk factors include travel more than 4 weeks before donation and sexual exposure. Minipool screening would have detected only 50% of the RNA\u2010positive donations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.14029","type":"journal-article","created":{"date-parts":[[2017,2,5]],"date-time":"2017-02-05T22:17:14Z","timestamp":1486333034000},"page":"762-769","source":"Crossref","is-referenced-by-count":63,"title":["First Zika\u2010positive donations in the continental United States"],"prefix":"10.1111","volume":"57","author":[{"given":"Susan A.","family":"Galel","sequence":"first","affiliation":[{"name":"Roche Molecular Systems, Inc. Pleasanton California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip C.","family":"Williamson","sequence":"additional","affiliation":[{"name":"Creative Testing Solutions St Petersburg Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Busch","sequence":"additional","affiliation":[{"name":"Blood Systems Research Institute San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Stanek","sequence":"additional","affiliation":[{"name":"Florida Department of Health Tallahassee Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bakkour","sequence":"additional","affiliation":[{"name":"Blood Systems Research Institute San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mars","family":"Stone","sequence":"additional","affiliation":[{"name":"Blood Systems Research Institute San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lu","sequence":"additional","affiliation":[{"name":"Blood Systems Research Institute San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jones","sequence":"additional","affiliation":[{"name":"QualTex Laboratories San Antonio Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan N.","family":"Rossmann","sequence":"additional","affiliation":[{"name":"Gulf Coast Regional Blood Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Lee","family":"Pate","sequence":"additional","affiliation":[{"name":"Roche Molecular Systems, Inc. Pleasanton California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the cobas Zika IND Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,5]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"95","article-title":"Zika virus and the never\u2010ending story of emerging pathogens and transfusion medicine","volume":"14","author":"Marano G","year":"2016","journal-title":"Blood Transfus"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2016.08.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0617"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.13.20751"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6514a3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6528e2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6503e1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13681"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1607262"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30883-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00562-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf5036"},{"key":"e_1_2_8_14_1","unstructured":"Case counts in the US [Internet]. Atlanta:Centers for Disease Control and Prevention;2016Nov 16 [cited 2016 Nov 20]. Available from:http:\/\/www.cdc.gov\/zika\/geo\/united-states.html."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.14.20761"},{"key":"e_1_2_8_16_1","unstructured":"U.S. Food and Drug Administration. Guidance for industry: recommendations for donor screening deferral and product management to reduce the risk of transfusion\u2010transmission of Zika virus. (February 2016) Silver Spring (MD): CBER Office of Communication Outreach and Development;2016."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6524e2"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6530e1"},{"key":"e_1_2_8_19_1","volume-title":"Guidance for industry: revised recommendations for reducing the risk of Zika virus transmission by blood and blood components","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"e_1_2_8_20_1","unstructured":"Zika MAC\u2010ELISA [Internet]. Atlanta:Centers for Disease Control and Prevention;2016[cited 2016 Nov 28]. Available from:http:\/\/www.fda.gov\/downloads\/MedicalDevices\/Safety\/EmergencySituations\/UCM488044.pdf."},{"key":"e_1_2_8_21_1","unstructured":"Advice for people living in or traveling to South Florida [Internet]. Atlanta:Centers for Disease Control and Prevention;2016Oct 19 [cited 2016 Nov 20]. Available from:http:\/\/www.cdc.gov\/zika\/intheus\/florida-update.html."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.26.30269"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2301.161394"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12764"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:36:03Z","timestamp":1694612163000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,5]]},"references-count":23,"journal-issue":{"issue":"3pt2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/trf.14029"],"URL":"https:\/\/doi.org\/10.1111\/trf.14029","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727277974.793528655","asserted-by":"object"}]},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,5]]}}}